Free On-line Access

SPCI - Sociedade Portuguesa de Cuidados Intensivos

Revista Brasileira de Terapia Intensiva

AMIB - Associação de Medicina Intensiva Brasileira

OFFICIAL JOURNAL OF THE ASSOCIAÇÃO BRASILEIRA DE MEDICINA INTENSIVA AND THE SOCIEDADE PORTUGUESA DE CUIDADOS INTENSIVOS

ISSN: 0103-507X
Online ISSN: 1982-4335

Ícone Fechar

How to Cite


 

Nardocci P, Gullo CE, Lobo SM. Severe virus influenza A H1N1 related pneumonia and community-acquired pneumonia: differences in the evolution. Rev Bras Ter Intensiva. 2013;25(2):123-129

 

 

2013;25(2):123-129
ORIGINAL ARTICLES

10.5935/0103-507X.20130023

Severe virus influenza A H1N1 related pneumonia and community-acquired pneumonia: differences in the evolution

Pneumonia grave por vírus influenza A H1N1 e pneumonia comunitária grave: diferenças na evolução

Paula Nardocci, Caio Eduardo Gullo, Suzana Margareth Lobo

Faculdade de Medicina de São José do Rio Preto - FAMERP, São José do Rio Preto, SP, Brazil

Conflicts of interest: None.

Submitted on January 11, 2013
Accepted on June 30, 2013

Corresponding author: Suzana Margareth Lobo, Serviço de Terapia intensiva do Hospital de Base Faculdade de Medicina de São José do Rio Preto, Avenida Brigadeiro Faria Lima, 5.544, Zip code: 15090-000 - São José do Rio Preto (SP), Brazil, E-mail: suzanaalobo@gmail.com

Abstract

OBJECTIVE: To analyze the clinical, laboratory and evolution data of patients with severe influenza A H1N1 pneumonia and compare the data with that of patients with severe community-acquired bacterial pneumonia.
METHODS: Cohort and retrospective study. All patients admitted to the intensive care unit between May 2009 and December 2010 with a diagnosis of severe pneumonia caused by the influenza A H1N1 virus were included in the study. Thirty patients with severe community-acquired pneumonia admitted within the same period were used as a control group. Severe community-acquired pneumonia was defined as the presence of at least one major severity criteria (ventilator or vasopressor use) or two minor criteria.
RESULTS: The data of 45 patients were evaluated. Of these patients, 15 were infected with H1N1. When compared to the group with community-acquired pneumonia, patients from the H1N1 group had significantly lower leukocyte counts on admission (6,728±4,070 versus 16,038±7,863; p<0.05) and lower C-reactive protein levels (Day 2: 15.1±8.1 versus 22.1±10.9 mg/dL; p<0.05). The PaO2/FiO2 ratio values were lower in the first week in patients with H1N1. Patients who did not survive the H1N1 severe pneumonia had significantly higher levels of C-reactive protein and higher serum creatinine levels compared with patients who survived. The mortality rate was significantly higher in the H1N1 group than in the control group (53% versus 20%; p=0.056, respectivelly).
CONCLUSION: Differences in the leukocyte count, C-reactive protein concentrations and oxygenation profiles may contribute to the diagnosis and prognosis of patients with severe influenza A H1N1 virus-related pneumonia and community-acquired pneumonia.

Keywords: Pneumonia, viral; Pneumonia, bacterial; Influenza A virus; H1N1 subtype .

INTRODUCTION

Traditionally, viral pneumonia is considered less severe than bacterial community-acquired pneumonia (CAP). However, with the influenza A H1N1 (H1N1) outbreak in 2009, this assertion underwent a significant change because most of the infected individuals progressed to Acute Respiratory Distress Syndrome (ARDS) and, in many cases, death.(1)

CAP is the leading cause of death from infectious diseases. The mortality rates are approximately 1% for outpatients and as high as 14% for hospitalized patients; mortality rates are even higher for those who require hospitalization in intensive care units (ICU).(2,3)

The 2009 influenza A H1N1 pandemic had significant morbidity,(4) and the first reports suggested high mortality even in young patients and in previously healthy middle-aged patients.(5) The hospitalization rates in countries in the southern hemisphere ranged from 23.6 to 30.6% for individuals with influenza A H1N1 2009; among these, 11.7 to 18.5% (3.6 to 4.4% of the total number of cases) were admitted to ICUs.(6) The mortality rates among those admitted to the ICU were 16(7) to 41%(1), and most of those patients required ventilatory support.(8)

Considering the severely ill patients, there was a high incidence of ARDS, the most common cause of death. Its lethality seems to be similar to that of seasonal influenza,(1) but it is greater than that reported for the respiratory coronavirus registered during the 2003 outbreak.(9) A study conducted in 11 ICUs from six cities in the state of Paraná (Brazil) included 63 suspected and 37 confirmed H1N1 cases and reported that most of the patients were young and that the mortality rate was 39.7%.(10)

The investigation of diagnostic and severity markers related to the nature of the infectious agent (bacterial versus viral) that caused the community-acquired pneumonia and those markers' association with the clinical outcomes will allow that prediction of an unfavorable evolution, if present, and can guide earlier interventions and treatment. The present study aimed to determine the clinical, epidemiological and laboratory differences between critically ill individuals with community-acquired pneumonia and those with severe pneumonia caused by the influenza A H1N1 virus.

METHODS

Retrospectively and prospectively collected data from adult patients admitted to the Division of Critical Care (Mixed-24 bed ICU) of the Hospital de Base de São José do Rio Preto were analyzed. Data were collected between May 2009 and December 2010 from patients with a diagnosis of severe pneumonia caused by the influenza A virus H1N1 (H1N1). This study was approved by the Institutional Research Ethics Committee and informed consent was waived due to its observational nature.

The infection with influenza A H1N1 was diagnosed using the real time polymerase chain reaction (RT-PCR) of the nasopharyngeal secretion or respiratory tract specimens. Severe pneumonia caused by influenza A H1N1 was defined in the presence of fever >38ºC, cough and clinical, laboratory and radiological conditions compatible with pneumonia and signs of worsening of the disease, which included the following: tachypnea (respiratory rate >25), hypoxia (arterial oxygen saturation - SaO2 <92% at room air and <94% in pregnant women), cyanosis, oliguria, altered level of consciousness, worsening of chronic disease and hypotension (systolic blood pressure <90 mmHg) or the use of vasopressor drugs (dopamine >5 µg/kg/minute or any dose of norepinephrine).(11,12)

H1N1 patients were matched at a 2:1 ratio with cases of severe CAP admitted to the ICU. Thus, the data used for comparison came from consecutive patients who were admitted to the ICU with severe CAP during the same period and for whom the diagnosis of influenza A H1N1 had not been cogitated or the RT-PCR of nasopharyngeal or respiratory tract specimens were negative. Severe CAP requiring ICU admission was characterized by the presence of one major severity criteria (the need for mechanical ventilation or vasopressors) or two minor criteria (systolic blood pressure <90 mmHg or mean blood pressure <70 mmHg, arterial oxygen pressure/fraction of inspired oxygen [PO2/FiO2] <250, respiratory rate >30/minute, urea >19.6 mg/dL, altered mental status, multilobar pneumonia, platelets <100,000 cells/mm3, leukopenia - <4 x 109 or hypothermia [body temperature <36ºC]).(2)

The laboratory data included in the analysis were obtained from the routine morning collection, which occurred between 5 and 6 am. Serum PCR levels were measured using turbidimetric immunoassay.

Statistical analysis

The results were expressed as the mean and standard deviation or median and 25th -75th percentiles. The statistical analysis used Student's t test to compare two groups of normally distributed continuous variables, and the Mann-Whitney test was used for non-normal distributions. Descriptive statistics were calculated for the quantitative variables, and they were analyzed using Fisher's test. P values <0.05 were considered significant.

RESULTS

The data of 45 patients were evaluated. Fifteen of those patients were admitted with H1N1 and 30 were admitted with CAP. The patients with H1N1 were younger (34.3±10.9 years versus 55.9±16.4 years in patients with CAP; p<0.001; Table 1). The proportion of patients requiring mechanical ventilation (86.7% versus 13.3%; p<0.05) and the mortality rate were higher in the H1N1 group than in the CAP group (53% versus 20%, respectively; p=0.056).

In patients with H1N1, the most frequent comorbidities were obesity, 53%; cardiovascular disease, 20%; and diabetes, 20%. In the CAP group, the most frequent comorbidities were cardiovascular diseases, 40%; tobacco smoking, 30%; and diabetes, 27% (Table 1). Obesity was significantly more prevalent in the H1N1 group (53%) than in the CAP group (6.6%), with p=0.02 (Table 1).

Compared with survivors, nonsurvivors of H1N1 were significantly older (40.2±9.2 versus 27.6±8.7 years; p=0.018), had higher serum lactate levels on admission (4.35±3.61 versus 1.53 ± 0.85 mEq/L; p=0.06) and had longer hospitalizations (not significant; Table 1).

Table 1 - Demographic data, clinical characteristics and outcomes from both groups
H1N1 CAP
Total S NS Total S NS
Number of patients 15 7 8 30 24 6
Male 9 (60.0) 6 (85.7) 3 (33.3) 21 (70.0) 17 (70.8) 4 (66.6)
Age (years) 34.3±10.9* 27.6±8.7 40.2±9.2# 55.9±16.4 58.2±18.9 55.3±16.1
Lactate at admission (mEq/L) 3.6±2.8 (N=7) 1.53±0.85 (N=3) 4.35±3.61 N= 4) 3.1±1.9 (N=28) 3.22±2.13 (N=22) 2.7±0.98 (N=6)
Comorbidities
Obesity 8 (53.3)* 3 (42.8) 5 (62.5) 2 (6.6) 2 (8.3) 0 (0.0)
CVD 3 (20.0) 1 (14.2) 2 (25.0) 12 (40.0) 10 (41.6) 2 (33.3)
Diabetes 3 (20.0) 2 (28.5) 1 (12.5) 8 (26.6) 5 (20.8) 3 (50.0)
Tobacco smoking 2 (13.3) 0 (0.0) 2 (25.0) 9 (30.0) 8 (33.3) 1 (16.6)
COPD 1 (6.6) 0 (0.0) 1 (12.5) 6 (20.0) 4 (16.6) 2 (33.3)
Alcoholism 0 (0) 0 (0.0) 0 (0.0) 4 (13.3) 3 (12.5) 1 (16.6)
CRF 0 (0) 0 (0.0) 0 (0.0) 1 (3.3) 1 (4.1) 0 (0.0)
Outcomes
Need for ventilator 13 (86.7) 7 (53.8) 6 (43.2) 3 (10.0) 2 (66.6) 1 (33.3)
Days of hospitalization 8.0 (5.0-15.0) 8.0 (6.0-11.0) 8.5 (2.7-24.0) 24 (15.7-28.2) 27.0 (19.2-9.5) 18.0 (9.0-3.7)
Days of ICU hospitalization 4.0 (2.0-7.0) 6.0 (4.0-7.0) 10 (4.2-28.7) 15.5 (8.7-4.2) 18.0 (9.2-4.7) 12.5 (7.2-8.2)

[i] CAP - community-acquired pneumonia; S - survivor; NS - nonsurvivor; CVD - cardiovascular disease; COPD - chronic obstructive pulmonary disease; CRF - chronic renal failure; ICU - intensive care unit. *p<0.05 versus CAP; #p<0.05 versus survivors. Results are expressed as number (%), mean±standard deviation (SD) or median (25%-75%).

Table 1 - Demographic data, clinical characteristics and outcomes from both groups

Compared with patients from the control group, patients from the H1N1 group had significantly lower leukocyte counts (Day 1: 6,728±4,070 versus 16,038±7,863 and Day 2: 7,957±5,981 versus 14,130±6,514; p<0.05 for both) and significantly lower serum PCR levels (Day 2: 15.1±8.1 versus 22.1±10.9 mg/dL, p<0.05; Table 2). H1N1 nonsurvivors had significantly higher CRP levels compared with survivors (Day 1: 21.9±2.9 versus 6.9±4.8 mg/dL; Day 2: 20.5±3.5 versus 10.6±8.2 mg/dL; Day 3: 20.3±4.1 versus 8.1±9.3 mg/dL; Day 4, 16.1±5.5 versus 5.6±6.8 mg/dL; p<0.05 for all; Table 2).

Table 2 - Inflammatory parameters during the first week of hospitalization for the two groups, H1N1 and community-acquired pneumonia survivors and nonsurvivors
H1N1 CAP
Total S NS Total S NS
Leukocytes D1 6,728±4,070 (N=14) 6,656±4,853 (N=7) 6,800±3,511 (N=7) 16,038±7,863 (N=29) 16,587±8,157 (N=23) 13,933±6,837 (N= 6)
Leukocytes D2 7,957±5,981 (N=14)* 5,886±3,458 (N=7) 10,029±7,453 (N=7) 14,130±6,514 (N=27) 15,376±6,841 (N=21) 9,767±2,026 (N=6)
Leukocytes D3 9,867±6,874 (N=12) 8,050±4,529 (N=6) 11,683±8,691 (N=6) 13,363±6,257 (N=29) 13,410±6,270 (N=23) 13,182±6,799 (N=6)
Leukocytes D4 9,565±5,962 (N=12) 9,530±4,873 (N=6) 96,00±7,379 (N=6) 12,636±7,792 (N=28) 13,070±8,513 (N=23) 10,640±2,285 (N=5)
Leukocytes D5 10,691±5,657 (N=11) 9,933±6,868 (N=6) 11,600±4,375 (N=5) 13,179±8,180 (N=28) 13,665±8,826 (N=23) 10,940±3,955 (N=5)
Leukocytes D6 11,210±5,821 (N=10) 8,983±5,894 (N=6) 14,550±4,355 (N=4) 12,708±7,820 (N=13) 13,291±8,375 (N=11) 9,500±2,828 (N=2)
Leukocytes D7 10,919±4,460 (N=7) 10,167±4,994 (N=3) 11,483±4,707 (N=4) 16,557±10,511 (N=7) 15,800±8,004 (N=18) 12,575±3,783 (N=4)
CRP D1 14.4±8.7 (N=12) 6.9±4.8 (N=6) 21.9±2.9 (N=6)# 18.0±10.9 (N=30) 18.2±11.7 (N=24) 17.2±8 (N=6)
CRP D2 15.1±8.1* (N=13) 10.6±8.2 (N=7) 20.5±3.5 (N=6)# 22.1±10.9 (N=27) 22.1±11.7 (N=22) 22±6.8 (N=5)
CRP D3 13.0±9.5 (N=10) 8.1±9.3 (N=6) 20.3±4.1 (N=4)# 20.5±10.5 (N=30) 20.8±10.7 (N=24) 19.4±10.1 (N=6)
CRP D4 11.3±8.1 (N=11) 5.6±6.8 (N=5) 16.1±5.5 (N=6)# 16.7±10.3 (N=29) 16.9±10.3 (N=24) 15.7±11.2 (N=5)
CRP D5 6.7±7.0 (N=11) 3.2±3.4 (N=6) 10.8±8.2 (N=5) 12.3±9.8 (N=28) 12.7±10.6 (N=23) 10.5±5.3 (N=5)
CRP D6 5.3±7.2 (N=9) 2.5±2.3 (N=5) 8.8±10.1 (N=4) 12.3±10.1 (N=26) 13.1±11 (N=21) 9.3±4.7 (N=5)
CRP D7 5.2±6.2 (N=8) 2.4±2.5 (N=4) 8.0 ±7.8 (N=4) 10.6±8.6 (N=28) 10.7±9.1 (N=23) 10.3±6.8 (N=5)

[i] CAP - community-acquired pneumonia; S - survivor; NS - nonsurvivor; CRP - C-reactive protein. Results are expressed as number (%), mean±standard deviation (SD) (number of measures). *p<0.05 versus CAP; #p<0.05 versus survivors.

Table 2 - Inflammatory parameters during the first week of hospitalization for the two groups, H1N1 and community-acquired pneumonia survivors and nonsurvivors

The PaO2/FiO2 ratio was significantly lower during the first week for patients with H1N1 (Table 3).

Nonsurvivors had lower PaO2/FiO2 values (Day 2: 54±43 versus 165±94) and higher plasma creatinine levels (Day 3: 1.72±0.59 versus 1.06±0.27 mg/dL; p<0.05) compared with survivors (Table 3). The platelet count values are described in table 3. Figure 1 shows the mean CRP (mg/dL) and PaO2/FiO2 for the H1N1 and CAP groups.

Table 3 - Oxygenation parameters, renal function and platelet count during the first week of hospitalization for both groups
H1N1 CAP
Total S NS Total S NS
P/F D1 121±92 (N=5) 165±94 (N=3) 54±43 (N=2) 205±94 (N=30) 208±93 (N=24) 192±106 (N=6)
P/F D2 145±113* (N=6) 283±4 (N=2) 76±46 (N=4)# 246±90 (N=25) 250±92 (N=19) 234±91 (N=6)
P/F D3 159±135 (N=6) 196±48 (N=2) 141±168 (N=4) 249±91 (N=27) 254±96 (N=23) 218±59 (N=4)
P/F D4 174±68* (N=5) 202 (N=1) 167±76 (N=4) 268±85 (N=29) 263±84 (N=24) 289±97 (N=5)
P/F D5 156±61 (N=5)* 217 (N=1) 140±59 (N=4) 254±68 (N=29) 265±68 (N=25) 201±37 (N=5)#
P/F D6 122±47 (N=6)* 138±81 (N=2) 113±34 (N=4) 285±87 (N=29) 283±83 (N=24) 294±113 (N=5)
P/F D7 97±31 (N=4)* 81±35 (N=2) 114±2 (N=2) 275±92 (N=29) 278±94 (N=24) 259±88 (N=5)
Creatinine (mg/dL) D1 1.23±0.3 (N=12) 1.2±0.37 (N=6) 1.2 ±0.33 (N=6) 1.39±0.6 (N=29) 1.34±0.64 (N=23) 1.62±0.43 (N=5)
Creatinine (mg/dL) D3 1.39±0.5 (N=10) 1.06±0.27 (N=5) 1.72±0.59 (N=5)# 1.22±0.7 (N=29) 1.32±0.84 (N=4) 1.15±0.39 (N=4)
Creatinine (mg/dL) D5 1.28±0.6 (N=11) 0.98±0.21 (N=6) 1.64±0.77 (N=5) 1.07±0.6 (N=28) 1.10±0.7 (N=23) 1.00±0.29 (N=4)
Creatinine (mg/dL) D7 1.25±0.6 (N=6) 0.95±0.35 (N=2) 2.40±0.69 (N=4) 1.03±0.5 (N=28) 1.01±0.61 (N=24) 1.13±0.44 (N=4)
Platelets (x103) D1 181±57 (N=14) 158±58 (N=7) 203±50 (N=7) 238±143 (N=28) 282±174 (N=23) 205±114 (N=6)
Platelets (x103) D2 174±43 (N=8) 160±44 (N=3) 182±45 (N=5) 214±96 (N=28) 244±109 (N=21) 163±48 (N=6)
Platelets (x103) D3 179±73 (N=7) 207±68 (N=5) 109±13 (N=2) 208±198 (N=28) 220±101 (N=23) 195±56 (N=6)
Platelets (x103) D4 188±63 (N=6) 194±59 (N=3) 182±78 (N=3) 198 ± 82 (N=28) 204±83 (N=23) 182±110 (N=5)
Platelets (x103) D5 274±149 (N=5) 312±141 (N=4) 121 (N=1) 219±102 (N=28) 209±87 (N=22) 211±121 (N=5)
Platelets (x103) D6 285±135 (N=6) 294±190 (N=3) 276±97 (N=3) 226±110 (N=28) 216±100 (N=16) 137±30 (N=2)
Platelets (x103) D7 210±35 (N=4) 240±6 (N=2) 215±62 (N=3) 270±101 (N=28) 287±117 (N=16) 235±71 (N=4)

[i]CAP - community-acquired pneumonia; S - survivor; NS - nonsurvivor; P/F - PaO2/FiO2 ratio. Results are expressed as number (%), mean±standard deviation (SD). *p<0.05 versus CAP; #p<0.05 versus survivors.

Table 3 - Oxygenation parameters, renal function and platelet count during the first week of hospitalization for both groups
Figure 1 - Mean values of C-reactive protein (mg/dL) and arterial oxygen pressure/fraction of inspired oxygen (PO2/FiO2) during the first week of evolution for the H1N1 (■) and community-acquired pneumonia (♦) groups.

DISCUSSION

In the present study, we observed that, compared with patients who were admitted with bacterial CAP, the H1N1 group had younger patients and a higher prevalence of obesity. Significant differences were observed in the leukocyte count, CRP and oxygenation profiles, and higher mortality was observed in the H1N1 group.

Patients with diabetes mellitus, cancer, cardiovascular, respiratory and autoimmune diseases and pregnant women (especially those in the second and third trimesters of pregnancy) also showed increased susceptibility to more severe disease.(10) In a Brazilian study, 27% of the patients with H1N1 were obese.(10) Obesity has been reported as a risk factor for severity and mortality among patients with swine flu.(8) A probable reason for this fact is the decrease in the functional residual capacity, which likely has an important impact during the evolution of H1N1.(10)

CRP is an acute-phase protein released immediately after the start of the inflammatory or tissue injury process. CRP serum concentration is determined by its synthesis rate, which depends on the intensity of the inflammatory stimulus. Studies have demonstrated the utility of serial CRP measurements as a tool for the diagnosis and monitoring of the response to CAP and nosocomial pneumonia treatment.(13-15) A high CRP serum level on admission to the emergency room was a predictor of ICU admission and need for mechanical ventilation.(16) However, the kinetics of serum CRP levels in patients with severe H1N1 pneumonia remain unknown to date.

Compared with patients from the CAP group, patients from the H1N1 group had significantly lower serum CRP levels and leukocyte counts, which suggest a lower inflammatory response compared with acute bacterial conditions and a possible viral infection. However, patients with H1N1 who did not survive had CRP levels that were higher than those of survivors and were similar to those found in the bacterial process. These data suggest that the patients who died had a stronger inflammatory response or a secondary bacterial infection.

A secondary bacterial infection was implicated in the increased morbidity and mortality of patients with influenza A H1N1 2009.(17,18) The most commonly identified agents were Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae and gram-negative bacilli. In fatal cases of H1N1 virus infection, the most evident histopathological findings were different degrees of alveolar injury with the presence of hyaline membrane and septal edema, necrotizing tracheitis and bronchiolitis, pulmonary vascular congestion, alveolar hemorrhage, pulmonary thromboembolism and bacterial coinfection in 26 to 38%.(19) A recent study reported that among patients with H1N1 infection, CRP serum levels were significantly higher in those who developed pneumonia compared with patients who did not develop pneumonia.(20)

PaO2/FiO2 values were significantly lower in patients with H1N1 than in patients with severe CAP who received mechanical ventilatory support. The main cause of death in patients with H1N1 is respiratory failure refractory to the usual mechanical ventilation.(21) Currently, the use of extracorporeal membrane oxygenation in these patients seems to be one of the most effective measures for reducing mortality.(21) The presence of severe hypoxemia in patients who died suggests that the medical centers that receive these patients should be prepared to offer this type of advanced life support to patients with severe hypoxemia.

The mortality rate in this series was 53% for patients with H1N1. Among ICU patients, the mortality rate is 16(7) to 41%(1) in different series, and most of the patients required prolonged ventilatory support.(8)

The major limitations of this study are its observational nature, the small sample size and the pairing performed by consecutive sample. Thus, other more adequate selection methods (such as the propensity score or by severity criteria) were not possible, which represent a potential selection bias). Other limitations were the inability to assess other markers of severity, such as procalcitonin and interleukin-6, and the fact that the study was conducted in a single center. However, the inclusion of a homogeneous population with severe forms of pneumonia supports the findings of the present study.

CONCLUSION

Usual laboratory tests may contribute to the differential diagnosis of severe community-acquired pneumonia and severe influenza A H1N1 pneumonia.

ACKNOWLEDGEMENTS

The authors thank the Scientific Initiation Scholarship fund from the Faculdade de Medicina de São José do Rio Preto.

REFERENCES

1

Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302(17):1880-7. Link DOILink PubMed

2

Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of AmericaAmerican Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72. Link DOILink PubMed

3

Mongardon N, Max A, Bouglé A, Pène F, Lemiale V, Charpentier J, et al. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care. 2012;16(4):R155 [Epub ahead of print]. Link DOILink PubMed

4

AlMazroa MA, Memish ZA, AlWadey AM. Pandemic influenza A (H1N1) in Saudi Arabia: description of the first one hundred cases. Ann Saudi Med. 2010;30(1):11-4. Link PubMed

5

Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, Vugia D, Harriman K, Matyas B, Glaser CA, Samuel MC, Rosenberg J, Talarico J, Hatch D; California Pandemic Working Group. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302(17):1896-902. Link DOILink PubMed

6

Maritz J, Maree L, Preiser W. Pandemic influenza A (H1N1) 2009: the experience of the first six months. Clin Chem Lab Med. 2010;48(1):11-21. Link DOILink PubMed

7

Bellomo R, Pettilä V, Webb SA, Bailey M, Howe B, Seppelt IM. Acute kidney injury and 2009 H1N1 influenza-related critical illness. Contrib Nephrol. 2010;165:310-4. Link PubMed

8

Rello J, Rodríguez A, Ibañez P, Socias L, Cebrian J, Marques A, Guerrero J, Ruiz-Santana S, Marquez E, Del Nogal-Saez F, Alvarez-Lerma F, Martínez S, Ferrer M, Avellanas M, Granada R, Maraví-Poma E, Albert P, Sierra R, Vidaur L, Ortiz P, Prieto del Portillo I, Galván B, León-Gil C; H1N1 SEMICYUC Working Group. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care. 2009;13(5):R148Link DOILink PubMed

9

Centers for Disease Control and Prevention. Revised U.S. surveillance case definition for severe acute respiratory syndrome (SARS) and update on SARS cases--United States and worldwide, December 2003. MMWR Morb Mortal Wkly Rep. 2003;52(49):1202-6. Link PubMed

10

Duarte PA, Venazzi A, Youssef NC, Oliveira MC, Tannous LA, Duarte CB, et al. Pacientes com infecção por vírus A (H1N1) admitidos em unidades de terapia intensiva do Estado do Paraná, Brasil. Rev Bras Ter Intensiva. 2009;21(3):231-6. Link DOI

11

Influenza A (H1N1). Situação epidemiológica da nova influenza A (H1N1) no Brasil, até semana epidemiológica 33 de 2009. Informe Epidemiológico. 2009;1(6):1-0. [Internet]. [citado 2009 Abr 1]. Disponível em http://portal.saude.gov.br/portal/arquivos/pdf/informe_influenza_se_33_25_08_2009.pdf.

12

Brasil; Ministério da Saúde. Secretaria de Atenção a Saúde; Departamento de Atenção Básica. Emergência de Saúde Pública de Importância Internacional - ESPII. Diretrizes para o enfrentamento à pandemia de influenza A (H1N1): ações da atenção primária à saúde. Brasília: Ministério da Saúde; 2009. Disponível em http://portal.saude.gov.br/portal/arquivos/pdf/protocolo_influenzaa_aps_atualizado.pdf

13

Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J. 2008;32(3):726-32. Link DOILink PubMed

14

Lisboa T, Seligman R, Diaz E, Rodriguez A, Teixeira PJ, Rello J. C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia. Crit Care Med. 2008;36(1):166-71. Link DOILink PubMed

15

Moreno MS, Nietmann H, Matias CM, Lobo SM. C-reactive protein: a tool in the follow-up of nosocomial pneumonia. J Infect. 2010;61(3):205-11. Link DOILink PubMed

16

Zimmerman O, Rogowski O, Aviram G, Mizrahi M, Zeltser D, Justo D, et al. C-reactive protein serum levels as an early predictor of outcome in patients with pandemic H1N1 influenza A vírus infection. BMC Infect Dis. 2010;10:288Link DOILink PubMed

17

Balcan D, Colizza V, Singer AC, Chouaid C, Hu H, Gonçalves B, et al. Modeling the critical care demand and antibiotics resources needed during the Fall 2009 wave of influenza A(H1N1) pandemic. PLoS Curr. 2009;1:RRN1133Link DOILink PubMed

18

Palacios G, Hornig M, Cisterna D, Savji N, Bussetti AV, Kapoor V, et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One. 2009;4(12):e8540Link DOILink PubMed

19

Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza; Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362(18):1708-19. Erratum in N Engl J Med. 2010;362(21):2039. Link DOILink PubMed

20

Milosevic I, Korac M, Zerjav S, Urosevic A, Lavadinovic L, Milosevic B, et al. Non-specific inflammatory parameters in patients with pandemic H1N1 influenza. Biomed Pharmacother. 2013;67(3):218-20. Link DOILink PubMed

21

Azevedo LC, Park M, Costa EL, Santos EV, Hirota A, Taniguchi LA, et al. Oxigenação extracorpórea por membrana na hipoxemia grave: hora de revermos nossos conceitos? J Bras Pneumol. 2012;38(1):7-12

[4] This study was conducted at the Division of Intensive Care, Hospital de Base de São José do Rio Preto, Faculdade de Medicina de São José do Rio Preto - FAMERP - São José do Rio Preto (SP), Brazil.

Submission On-line

Indexed in

Scopus

SciELO

LILACS

Associação de Medicina Intensiva Brasileira - AMIB

Rua Arminda nº 93 - 7º andar - Vila Olímpia - São Paulo, SP, Brasil - Tel./Fax: (55 11) 5089-2642 | e-mail: rbti.artigos@amib.org.br

GN1 - Systems and Publications